Back to today’s briefing

Story perspectives

Funding Cuts Threaten Pioneering Alzheimer's Drug Trial

4/29/2025

48 4

Summary

Story summary

The DIAN trial is pioneering the use of the anti-amyloid drug remternetug to halt Alzheimer’s in those genetically at risk, aiming to intervene before symptoms arise. However, recent funding cuts from the NIH jeopardize this crucial research. Experts stress the importance of a multifaceted approach, targeting both amyloid and tau to truly fight this devastating disease.

1 of 1

Story summary

The DIAN trial is pioneering the use of the anti-amyloid drug remternetug to halt Alzheimer’s in those genetically at risk, aiming to intervene before symptoms arise. However, recent funding cuts from the NIH jeopardize this crucial research. Experts stress the importance of a multifaceted approach, targeting both amyloid and tau to truly fight this devastating disease.